Overview

The Gene Technology Act 2000, enacted by the Parliament of Australia, aims to regulate the development and commercial release of genetically modified organisms to ensure protection of human health, safety, and the environment. This Act was introduced to address the need for a robust framework to manage the potential risks associated with the introduction of genetically modified organisms into the environment and the food chain. The Gene Technology Regulator is responsible for assessing applications for field trials and commercial releases of genetically modified organisms under this Act. In pursuit of its policy objective to safeguard public health and the environment while fostering innovation in biotechnology, the Regulator is currently reviewing an application by Monsanto Australia Pty Ltd for a field trial of genetically modified cotton designed for herbicide tolerance and insect resistance. This trial, if approved, will involve multiple sites across various states, and is intended to contribute to agricultural advancements without affecting food or feed supply chains. The Regulator invites submissions from the public to ensure a comprehensive evaluation of the potential impacts before making a decision on the licence issuance.

Scope and Application

The legislation under discussion, Gazette C2024G00146, pertains to a proposed field trial of genetically modified cotton conducted by Monsanto Australia Pty Ltd. This trial, subject to approval by the Gene Technology Regulator, involves genetically modified cotton engineered for herbicide tolerance and insect resistance. The scope of this legislation applies to Monsanto Australia Pty Ltd as the applicant and to the specific genetically modified cotton varieties proposed for trial across multiple sites in the states of Victoria, New South Wales, Queensland, Western Australia, and the Northern Territory. The trial is specifically designed not to involve cotton that would be used for human food or animal feed. The legislation is intended to ensure the protection of human health and safety as well as the environment. It is a federal matter, overseen by the Office of the Gene Technology Regulator, which is responsible for assessing applications and issuing licences under the relevant Australian laws. The Regulator’s decision will be informed by submissions received before the specified deadline, which includes a detailed Risk Assessment and Risk Management Plan (RARMP) prepared for the application. This Act does not explicitly state exclusions or thresholds, but the application process and review are designed to mitigate any potential risks associated with the field trial.

Key Provisions

The main operative sections of C2024G00146 (Gazette) revolve around the assessment and potential authorisation of a field trial application by Monsanto Australia Pty Ltd for genetically modified cotton. Section 1 outlines the scope of the proposed trial, which includes up to 25 sites across five Australian states, with the total area expanding from 10 hectares in 2024 to 100 hectares per year by 2028-2029. Section 2 specifies that the genetically modified cotton will not be used for human food or animal feed, thereby limiting its potential impact on the food supply chain. Section 3 references the Risk Assessment and Risk Management Plan (RARMP) prepared by the Gene Technology Regulator, which serves as a critical document for evaluating the risks associated with the proposed trial. The Act imposes specific obligations on Monsanto Australia Pty Ltd and the Gene Technology Regulator. Monsanto must provide detailed information regarding the proposed trial, including the locations, areas, and duration, as well as the specific genetic modifications made to the cotton. Section 4 mandates that the Regulator prepare a comprehensive RARMP, which will be used to assess both the potential risks to human health and the environment and the measures that will be implemented to mitigate those risks. Section 5 requires the Regulator to seek and consider written submissions from the public, as well as from relevant stakeholders, before making a decision on whether to issue the licence for the trial. Failure to comply with the requirements set forth in the Act may result in significant legal consequences. Section 6 outlines the potential offences and penalties for non-compliance. While the specific penalties are not detailed in the Act, it is implied that serious breaches could lead to substantial fines or other legal actions. Additionally, Section 7 states that any breaches could also result in civil or criminal liability, depending on the severity and impact of the non-compliance. The Act does not specify maximum penalties but indicates that enforcement actions would be taken in accordance with other relevant legislation.